Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Change in Accured Expenses (2019 - 2025)

Historic Change in Accured Expenses for IDEAYA Biosciences (IDYA) over the last 7 years, with Q3 2025 value amounting to $7.5 million.

  • IDEAYA Biosciences' Change in Accured Expenses rose 15934.37% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.5 million, marking a year-over-year increase of 5907.64%. This contributed to the annual value of $10.8 million for FY2024, which is 56018.35% up from last year.
  • IDEAYA Biosciences' Change in Accured Expenses amounted to $7.5 million in Q3 2025, which was up 15934.37% from $4.8 million recorded in Q2 2025.
  • Over the past 5 years, IDEAYA Biosciences' Change in Accured Expenses peaked at $7.5 million during Q3 2025, and registered a low of -$2.8 million during Q2 2023.
  • For the 5-year period, IDEAYA Biosciences' Change in Accured Expenses averaged around $1.9 million, with its median value being $2.3 million (2024).
  • Examining YoY changes over the last 5 years, IDEAYA Biosciences' Change in Accured Expenses showed a top increase of 66811.15% in 2023 and a maximum decrease of 39928.57% in 2023.
  • Over the past 5 years, IDEAYA Biosciences' Change in Accured Expenses (Quarter) stood at $476000.0 in 2021, then plummeted by 32.14% to $323000.0 in 2022, then skyrocketed by 668.11% to $2.5 million in 2023, then decreased by 8.34% to $2.3 million in 2024, then soared by 230.17% to $7.5 million in 2025.
  • Its Change in Accured Expenses was $7.5 million in Q3 2025, compared to $4.8 million in Q2 2025 and $2.9 million in Q1 2025.